A significant clinical study is currently underway at Linköping University in Sweden, investigating whether the psychedelic compound psilocybin may help people living with persistent, long-term grief. For bereaved individuals whose suffering continues long after their loss, researchers are exploring a possible future treatment—but there are currently no results showing that the method is effective.

Prolonged Grief – When Loss Continues to Dominate Life

There is an important distinction between normal grief and what researchers and clinicians refer to as Prolonged Grief Disorder (PGD). The diagnosis is now included in both the World Health Organization's ICD-11 classification system and the American psychiatric diagnostic manual DSM-5-TR, although the diagnostic criteria differ somewhat between the two.

Under DSM-5-TR, adults can be diagnosed no earlier than twelve months after a bereavement, provided the grief remains persistent and causes significant impairment in everyday life.

Normal grief is a natural process in which feelings of loss and sadness gradually become less overwhelming over time. Sometimes, however, grief becomes so profound and persistent that people remain emotionally stuck. They struggle to move forward, adapt to life after the loss, and continue to experience significant suffering long after the death of a loved one. According to the diagnostic criteria, prolonged grief causes substantial distress and affects daily life, work, and social relationships.

According to Rebecca Böhme, neuroscientist and principal investigator of the study at the Centre for Social and Affective Neuroscience (CSAN) at Linköping University, prolonged grief represents something very specific.

"It is when someone has truly become stuck in their grief after twelve months and cannot move forward, experiencing considerable suffering."

Böhme also speaks from personal experience. She lost her mother twenty years ago—a loss she has described as particularly difficult to process. Four years ago, she also lost her father. These personal experiences inspired a scientific question: what neurological mechanisms underlie prolonged grief, and could they potentially be influenced?


Psilocybin and Brain Plasticity – A Hypothesis Under Investigation

Psilocybin is a psychedelic compound that occurs naturally in certain mushroom species. Researchers believe it may increase the brain's plasticity—its ability to form new neural connections and become more receptive to new information. However, this mechanism has not yet been fully established, and much remains to be understood.

The study is based on the hypothesis that if psilocybin temporarily increases brain plasticity, combined with professional therapeutic support, it may become easier for people with prolonged grief to process their loss and reconsider deeply established patterns of thought.

The aim is not that psilocybin should "remove" grief. Rather, researchers hope it may create a therapeutic window in which new understanding, acceptance, and psychological adaptation become possible.


When Does Grief Become an Illness?

The study also raises a broader and more philosophical question:

When should grief become something that healthcare treats?

Swedish philosopher Fredrik Svenaeus has criticised the diagnosis as an example of medicalisation—the risk that a deeply human experience becomes framed primarily as a medical condition, despite grief also being shaped by existential, social, and cultural factors.

Supporters of the diagnosis, including Rebecca Böhme, argue that prolonged grief only partially overlaps with depression and other psychiatric disorders, and that a clearly defined diagnosis is necessary if the condition is to be studied scientifically at all. For people whose grief results in long-lasting and severe suffering, recognition within healthcare may also provide access to better support and future treatment options.

This tension is not resolved by the current study, but it makes the research questions even more important:

Who needs treatment? What should that treatment look like? And where should we draw the line between normal grief and prolonged grief?

How the Study Works

The study is randomised and double-blind. Participants are assigned to receive different doses of psilocybin—according to previous reporting, either a high dose or a very low dose—and neither the participants nor the research team know which dose any individual receives. This design allows researchers to compare outcomes between the groups as reliably as possible while reducing the influence of expectations on the results.

Participants make several visits to Linköping University Hospital. During the study they undergo, among other things:

  • An initial telephone interview to determine whether they meet the study's eligibility criteria.

  • A medical assessment, including blood tests and an ECG.

  • Functional magnetic resonance imaging (fMRI) to examine brain activity.

  • Possible transcranial magnetic stimulation (TMS), a technique used to investigate brain plasticity.

The clinical trial is being conducted at the Department of Psychiatry in Linköping, Region Östergötland, in collaboration with Linköping University. Linköping University is the study sponsor, and the trial has been reviewed and approved by the Swedish regulatory medicines authority.


Important to Know

This study is not about people using psychedelic mushrooms on their own or engaging in any form of self-medication.

The treatment takes place:

  • Within the healthcare system – at the Department of Psychiatry in Linköping.

  • Under medical supervision – participants undergo comprehensive health assessments before taking part.

  • With professional support – participants meet with a therapist before and after the dosing session and are monitored by study staff throughout the 7–8-hour treatment session. A physician is available should any medical issues arise.

  • Following careful screening – only individuals considered suitable and safe to participate are enrolled.

Psilocybin remains an illegal controlled substance in Sweden, and this study should not be interpreted as a recommendation for personal use. The treatment being investigated takes place under carefully controlled medical conditions following thorough clinical assessment.


A Long Way to Go – But Already Important

The researchers plan to include 120 participants in the study. So far, only a small number of people have completed treatment, meaning that no results are yet available.

Even if the study were to demonstrate positive effects, many further clinical trials and regulatory reviews would still be required before any treatment could become available within routine healthcare.

Nevertheless, the existence of the study is significant in itself. It reflects a growing recognition that prolonged grief is not only an existential or psychological experience but also a condition that can be investigated scientifically. Researchers hope to better understand the biological mechanisms involved and whether they may eventually be influenced safely and effectively.

For professionals working in bereavement care, funeral services, and healthcare, the research raises both hope and important questions. Hope that new treatment options may one day become available for people trapped in prolonged suffering—but also questions about who should be offered such treatment, how it should complement existing bereavement support, and what ethical considerations must be addressed before treatments of this kind could become part of clinical practice.

These are questions that will need to be answered as the research progresses. For now, however, scientists in Linköping continue their work to better understand how the human brain processes grief—knowledge that may one day contribute to new ways of helping people whose grief no longer heals with time.


Read also:

Can Psychedelic Therapy Ease Death Anxiety? New Research Offers Hope at the End of Life

– About the first stage of the grieving process: how researchers are exploring ways to ease existential suffering when life is drawing to a close.

Sources

This article is based on peer-reviewed scientific studies, information published by universities and established news reporting.

Original sources are available below.